R&D channel feed

At AS­CO, cell ther­a­pies for dead­ly form of brain can­cer make ear­ly strides

3 weeks ago
Cell/Gene Tx

Lyra’s stock soars on Phase 3 suc­cess for chron­ic rhi­nos­i­nusi­tis treat­ment

3 weeks ago

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

3 weeks ago
Deals
China

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

3 weeks ago

En­her­tu com­bo has the mak­ings of a new stan­dard in HER2-pos­i­tive breast can­cer

3 weeks ago
Pharma

Sanofi to snap up Blue­print Med­i­cines and mas­to­cy­to­sis drug Ay­vak­it for $9.1B

3 weeks ago
Deals

Kymera un­veils ‘ex­cep­tion­al’ Phase 1 da­ta for its Dupix­ent-in-a-pill pro­gram

3 weeks ago

Ve­ra posts pos­i­tive Phase 3 rare kid­ney dis­ease da­ta, but crowd­ed mar­ket looms

3 weeks ago
Pharma

In race with Merus, Bicara makes the case for two-year sur­vival da­ta

3 weeks ago

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

3 weeks ago

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

3 weeks ago

Take­da, Pro­tag­o­nist un­veil ple­nary da­ta for po­ten­tial block­buster rare blood dis­ease drug

3 weeks ago

Im­mat­ics re­ports more ear­ly-stage da­ta for melanoma cell ther­a­py with piv­otal tri­al un­der­way

3 weeks ago
Cell/Gene Tx

En­her­tu ex­tends life by three months for some stom­ach can­cer pa­tients, study finds

3 weeks ago
Pharma

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

3 weeks ago
Pharma

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

3 weeks ago

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

3 weeks ago

Q&A: Why for­mer Sen. Kyrsten Sine­ma is back­ing a psy­che­del­ic med­i­cine with po­ten­tial­ly more up­side, but more risk

3 weeks ago
People

Pfiz­er's Braftovi com­bo dou­bles sur­vival time for some col­orec­tal can­cer pa­tients

3 weeks ago
Pharma

Sanofi, Re­gen­eron re­port un­der­whelm­ing COPD da­ta for IL-33 an­ti­body, shares drop

3 weeks ago

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

3 weeks ago

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

4 weeks ago

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

4 weeks ago
Pharma

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

4 weeks ago
First page Previous page 123456 Next page Last page
A service from the Financial Times